^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | exemestane (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
(Approved for Estrogen Receptor Positive Breast Cancer)
New
Excerpt:
AROMASIN is an aromatase inhibitor indicated for:...adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy...
Source:
Title:
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Excerpt:
...Primary tumor cells or tumor cells of a metastatic site can be ER-positive and/or PgRpositive or ER-negative/PgR-negative ....
Trial ID:
Source:
Title:
Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer
Excerpt:
...- Inoperable estrogen receptor positive, Her-2 negative advanced breast cancer...
Trial ID:
Less C2 evidence
Source:
Title:
Optimal treatment duration of neoadjuvant endocrine therapy in women aged 60 years or older with estrogen receptor-positive, HER2-negative invasive breast cancer
Published date:
11/30/2020
Excerpt:
Inclusion criteria were women aged ≥ 60 years with Stage II or III breast cancer classified as estrogen receptor–positive / human epidermal growth factor receptor 2–negative….Patients took exemestane 25 mg per day for at least 3 years after starting the treatment unless progression was observed....Of all 24 patients, the maximal response was identified in 18 (75%).
DOI:
https://doi.org/10.1272/jnms.jnms.2021_88-509
Test:
